3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
Doxorubicin
9
Ifosfamide
8
Radiotherapy
6
Neoadjuvant Therapy
3
Chemotherapy, Adjuvant
3
Trabectedin
2
Filgrastim
2
Etoposide
2
pembrolizumab
1
pegfilgrastim
1
olaratumab
1
milademetan
1
indolepropanol phosphate
1
brigimadlin
1
X-Rays
1
Watchful Waiting
1
Vincristine
1
Surgical Procedures, Operative
1
Specimen Handling
1
Radiotherapy, Conformal
1
Observation
1
Epirubicin
1
Diathermy
1
Dactinomycin
1
Dacarbazine
1
Cyproheptadine
1
Cyclophosphamide
1
Combined Modality Therapy
1
Carboplatin
1
Brachytherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Liposarcoma
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts